Sagimet Biosciences Inc. Series A Common Stock SGMT
i
Market datapartial · fetched 2026-11-13T18:51:58.886Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T18:51:30.169646441Z
FundamentalsAlpha Vantage · unavailable
Sagimet Biosciences Inc. Series A Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 14.40 | 91.6% | 41.7% | 8.29 | 94.8% | 24.0% |
| 25Δ | 13.02 | 83.5% | 29.1% | 8.74 | 92.2% | 20.8% |
| 30Δ | 12.27 | 80.7% | 22.9% | 9.19 | 89.5% | 17.6% |
| 35Δ | 11.90 | 81.1% | 20.6% | 9.64 | 86.8% | 14.4% |
| 40Δ | 11.54 | 81.5% | 18.3% | 10.07 | 84.6% | 11.6% |
| 45Δ | 11.17 | 81.9% | 16.0% | 10.44 | 84.0% | 10.4% |
| 50Δ | 10.80 | 82.3% | 13.7% | 10.81 | 83.4% | 9.1% |
| 55Δ | 10.44 | 82.8% | 11.4% | 11.17 | 82.8% | 7.8% |
| 60Δ | 10.07 | 83.2% | 9.1% | 11.54 | 82.2% | 6.5% |
| 65Δ | 9.65 | 84.7% | 7.7% | 11.91 | 81.6% | 5.2% |
| 70Δ | 9.22 | 86.6% | 6.5% | 12.28 | 81.0% | 4.0% |
| 75Δ | 8.78 | 88.4% | 5.4% | |||
| 80Δ | 8.35 | 90.3% | 4.2% | |||
20Δ
- Pseudo strike
- 14.40
- IV
- 91.6%
- B/E move
- 41.7%
- Pseudo strike
- 8.29
- IV
- 94.8%
- B/E move
- 24.0%
25Δ
- Pseudo strike
- 13.02
- IV
- 83.5%
- B/E move
- 29.1%
- Pseudo strike
- 8.74
- IV
- 92.2%
- B/E move
- 20.8%
30Δ
- Pseudo strike
- 12.27
- IV
- 80.7%
- B/E move
- 22.9%
- Pseudo strike
- 9.19
- IV
- 89.5%
- B/E move
- 17.6%
35Δ
- Pseudo strike
- 11.90
- IV
- 81.1%
- B/E move
- 20.6%
- Pseudo strike
- 9.64
- IV
- 86.8%
- B/E move
- 14.4%
40Δ
- Pseudo strike
- 11.54
- IV
- 81.5%
- B/E move
- 18.3%
- Pseudo strike
- 10.07
- IV
- 84.6%
- B/E move
- 11.6%
45Δ
- Pseudo strike
- 11.17
- IV
- 81.9%
- B/E move
- 16.0%
- Pseudo strike
- 10.44
- IV
- 84.0%
- B/E move
- 10.4%
50Δ
- Pseudo strike
- 10.80
- IV
- 82.3%
- B/E move
- 13.7%
- Pseudo strike
- 10.81
- IV
- 83.4%
- B/E move
- 9.1%
55Δ
- Pseudo strike
- 10.44
- IV
- 82.8%
- B/E move
- 11.4%
- Pseudo strike
- 11.17
- IV
- 82.8%
- B/E move
- 7.8%
60Δ
- Pseudo strike
- 10.07
- IV
- 83.2%
- B/E move
- 9.1%
- Pseudo strike
- 11.54
- IV
- 82.2%
- B/E move
- 6.5%
65Δ
- Pseudo strike
- 9.65
- IV
- 84.7%
- B/E move
- 7.7%
- Pseudo strike
- 11.91
- IV
- 81.6%
- B/E move
- 5.2%
70Δ
- Pseudo strike
- 9.22
- IV
- 86.6%
- B/E move
- 6.5%
- Pseudo strike
- 12.28
- IV
- 81.0%
- B/E move
- 4.0%
75Δ
- Pseudo strike
- 8.78
- IV
- 88.4%
- B/E move
- 5.4%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 8.35
- IV
- 90.3%
- B/E move
- 4.2%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 82.98% | |
| 97.42% | |
| 98.96% | |
| 80.80% | |
| 114.02% | |
| 99.27% | |
| 89.43% | |
| 103.91% | |
| 91.63% | |
| 102.87% |
Biotechnology
SION
Sionna Therapeutics, Inc. is an innovative biotechnology company focused on developing advanced therapies for neurodegenerative disorders, notably Alzheimer's and Parkinson's…
More →SLDB
Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States. The company is headquartered in…
More →SLN
Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology, cardiovascular, and other…
More →SLS
SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications of cancer in the…
More →SMMT
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America, and Europe. The…
More →SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.
More →